6.86
price up icon104.78%   3.51
pre-market  시장 영업 전:  6.85   -0.01   -0.15%
loading
전일 마감가:
$3.35
열려 있는:
$6.88
하루 거래량:
24.71M
Relative Volume:
15.00
시가총액:
$552.48M
수익:
$414.29M
순이익/손실:
$-99.81M
주가수익비율:
-5.1393
EPS:
-1.3348
순현금흐름:
$-28.65M
1주 성능:
+100.58%
1개월 성능:
+89.50%
6개월 성능:
+101.76%
1년 성능:
-54.24%
1일 변동 폭
Value
$6.84
$6.92
1주일 범위
Value
$3.33
$6.92
52주 변동 폭
Value
$3.08
$15.36

애콜레이드 Stock (ACCD) Company Profile

Name
명칭
Accolade Inc
Name
전화
610-834-2989
Name
주소
660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING
Name
직원
2,400
Name
트위터
Name
다음 수익 날짜
2025-01-09
Name
최신 SEC 제출 서류
Name
ACCD's Discussions on Twitter

ACCD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Health Information Services icon
ACCD
Accolade Inc
6.86 552.48M 414.29M -99.81M -28.65M -1.3348
Health Information Services icon
VEEV
Veeva Systems Inc
217.30 35.28B 2.66B 665.91M 1.08B 4.05
Health Information Services icon
SOLV
Solventum Corp
68.96 11.91B 8.26B 66.00M 1.17B 0.3682
Health Information Services icon
DOCS
Doximity Inc
55.00 10.27B 516.85M 174.11M 217.38M 0.87
Health Information Services icon
HQY
Healthequity Inc
99.74 8.64B 1.15B 96.70M -161.99M 1.09
Health Information Services icon
WAY
Waystar Holding Corp
37.51 6.45B 906.14M -52.62M 89.62M -0.3621

애콜레이드 Stock (ACCD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-06-28 재확인 Needham Buy
2024-02-26 개시 Leerink Partners Outperform
2024-01-17 재개 DA Davidson Neutral
2024-01-03 개시 Barclays Equal Weight
2023-05-24 업그레이드 BofA Securities Neutral → Buy
2023-04-12 개시 Stephens Overweight
2023-03-23 업그레이드 Guggenheim Neutral → Buy
2023-02-09 다운그레이드 Jefferies Buy → Hold
2023-02-02 개시 Raymond James Outperform
2022-09-08 재개 Piper Sandler Overweight
2022-09-07 개시 Truist Buy
2022-08-12 개시 DA Davidson Buy
2022-05-02 업그레이드 Wells Fargo Underweight → Equal Weight
2022-04-29 다운그레이드 BTIG Research Buy → Neutral
2022-04-29 다운그레이드 BofA Securities Buy → Neutral
2022-04-29 다운그레이드 Credit Suisse Outperform → Neutral
2022-04-29 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-04-29 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-04-11 개시 Wells Fargo Underweight
2022-04-07 개시 Guggenheim Neutral
2022-04-01 재개 Credit Suisse Outperform
2022-02-11 개시 Goldman Buy
2021-12-02 개시 Jefferies Buy
2021-09-30 개시 Berenberg Buy
2021-09-17 업그레이드 Robert W. Baird Neutral → Outperform
2021-05-28 개시 Robert W. Baird Neutral
2021-05-06 업그레이드 SVB Leerink Mkt Perform → Outperform
2021-04-15 개시 Needham Buy
2021-03-11 재개 Goldman Buy
2021-01-15 업그레이드 Credit Suisse Neutral → Outperform
2021-01-07 개시 BTIG Research Buy
2020-12-08 개시 Canaccord Genuity Buy
2020-09-22 개시 DA Davidson Buy
2020-07-27 개시 BofA Securities Buy
2020-07-27 개시 Credit Suisse Neutral
2020-07-27 개시 Goldman Buy
2020-07-27 개시 Morgan Stanley Overweight
2020-07-27 개시 Piper Sandler Overweight
2020-07-27 개시 Robert W. Baird Outperform
2020-07-27 개시 SVB Leerink Outperform
모두보기

애콜레이드 주식(ACCD)의 최신 뉴스

pulisher
07:09 AM

Accolade (NASDAQ:ACCD) Rating Lowered to Hold at Leerink Partnrs - MarketBeat

07:09 AM
pulisher
Jan 09, 2025

Transcarent to acquire health advocacy and primary care company Accolade for $621m - MSN

Jan 09, 2025
pulisher
Jan 09, 2025

Stifel Nicolaus Reaffirms Hold Rating for Accolade (NASDAQ:ACCD) - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Estimate suggests Accolade may outperform with a potential 320% upside - Dataconomy

Jan 09, 2025
pulisher
Jan 09, 2025

Accolade, with 500 employees in Montco, to be acquired in $621M deal - The Business Journals

Jan 09, 2025
pulisher
Jan 09, 2025

Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Raymond James - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Accolade to be acquired by Transcarent for $7.03 per share in cash - Yahoo Finance

Jan 09, 2025
pulisher
Jan 09, 2025

How Accolade stock pulled off a 105% jump - Dataconomy

Jan 09, 2025
pulisher
Jan 09, 2025

Stifel downgrades Accolade stock as competing bids deemed unlikely - Investing.com

Jan 09, 2025
pulisher
Jan 09, 2025

Stifel Downgrades Accolade Inc. (ACCD) to Hold - StreetInsider.com

Jan 09, 2025
pulisher
Jan 09, 2025

Raymond James Downgrades Accolade Inc. (ACCD) to Market Perform - StreetInsider.com

Jan 09, 2025
pulisher
Jan 09, 2025

Earnings Scheduled For January 9, 2025 - Benzinga

Jan 09, 2025
pulisher
Jan 08, 2025

Accolade Gets a Do-Over With Transcarent’s $621M Acquisition - MedCity News

Jan 08, 2025
pulisher
Jan 08, 2025

Seattle health care company to go private in $621 million acquisition deal - The Business Journals

Jan 08, 2025
pulisher
Jan 08, 2025

ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc.ACCD - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

Truist maintains Buy on Accolade stock, reiterates $7.50 target By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade's (ACCD) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

What Transcarent's $621M Acquisition of Accolade Means for Behavioral Health - Behavioral Health Business

Jan 08, 2025
pulisher
Jan 08, 2025

Why Is Accolade Stock Trading Over 100% On Tuesday? - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

What's Going On With Accolade Stock Wednesday? - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

Truist maintains Buy on Accolade stock, reiterates $7.50 target - Investing.com India

Jan 08, 2025
pulisher
Jan 08, 2025

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Leerink Partners - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Wilson Sonsini, Cooley Lead $621M Take-Private Of Accolade - Law360

Jan 08, 2025
pulisher
Jan 08, 2025

Geode Capital Management Increases Stake in Accolade, Inc. – Market - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Inc. (ACCD): Q3 2025 Earnings Preview and Stock Outlook – Market - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Halper Sadeh LLC Investigates Accolade, Inc. Sale to Transcarent for Fairness to Shareholders - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent to acquire fellow health benefits navigator Accolade for $621M - Healthcare Dive

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (ACCD) Stock Update: Analyst Ratings and Market Performance – Market - HPBL

Jan 08, 2025
pulisher
Jan 08, 2025

Truist Securities Reiterates Buy Rating on Accolade Inc. (ACCD) - StreetInsider.com

Jan 08, 2025
pulisher
Jan 08, 2025

Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Accolade, Inc.ACCD - Longview News-Journal

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (NASDAQ:ACCD) Shares Gap UpWhat's Next? - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade - GeekWire

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent to acquire Accolade for $621 million creating benefits tech giant - STAT

Jan 08, 2025
pulisher
Jan 08, 2025

ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders - Business Wire

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Acquired by Transcarent in Strategic Merger - TipRanks

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade stock soars on $621M Transcarent acquisition deal - Investing.com

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent to acquire health benefits platform Accolade in $621M deal - Fierce healthcare

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade (ACCD) to Resume Trading at 9 am - StreetInsider.com

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent To Acquire Accolade - GlobeNewswire

Jan 08, 2025
pulisher
Jan 08, 2025

Transcarent To Acquire Accolade (ACCD) for $7.03 per share - StreetInsider.com

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Exp - GuruFocus.com

Jan 08, 2025
pulisher
Jan 08, 2025

Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Jan 08, 2025
pulisher
Jan 07, 2025

Transcarent, Inc. agreed to acquire Accolade, Inc. from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others. - Marketscreener.com

Jan 07, 2025
pulisher
Jan 06, 2025

Accolade’s chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Nigeria

Jan 06, 2025
pulisher
Jan 06, 2025

AcCOLADE EVP general counsel sells shares worth $1,338 - Investing.com India

Jan 06, 2025
pulisher
Jan 06, 2025

Accolade's chief accounting officer sells shares worth $1,785 - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

AcCOLADE EVP general counsel sells shares worth $1,338 By Investing.com - Investing.com Australia

Jan 06, 2025
pulisher
Jan 06, 2025

Accolade's chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Australia

Jan 06, 2025
pulisher
Dec 29, 2024

Newport News-based ivWatch receives accolades for life-saving technology - The Virginian-Pilot

Dec 29, 2024

애콜레이드 (ACCD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

애콜레이드 주식 (ACCD) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
McHugh Colin
Chief Accounting Officer
Jan 03 '25
Sale
3.41
524
1,785
62,066
Cavanaugh Robert N
President
Jan 02 '25
Option Exercise
0.00
1,569
0
214,864
Cavanaugh Robert N
President
Jan 03 '25
Sale
3.41
553
1,884
214,311
SINGH RAJEEV
Chief Executive Officer
Jan 02 '25
Option Exercise
0.00
3,786
0
819,637
SINGH RAJEEV
Chief Executive Officer
Jan 03 '25
Sale
3.41
1,158
3,945
818,479
Barnes Stephen H.
Chief Financial Officer
Jan 02 '25
Option Exercise
0.00
1,569
0
222,032
Barnes Stephen H.
Chief Financial Officer
Jan 03 '25
Sale
3.41
535
1,823
221,497
Eskew Richard
EVP General Counsel
Jan 02 '25
Option Exercise
0.00
1,146
0
63,653
Eskew Richard
EVP General Counsel
Jan 03 '25
Sale
3.41
393
1,339
63,260
$21.16
price up icon 0.33%
$20.93
price up icon 3.10%
health_information_services WGS
$96.57
price down icon 0.48%
$17.32
price down icon 0.12%
health_information_services TEM
$37.49
price down icon 3.56%
health_information_services WAY
$37.51
price up icon 0.03%
자본화:     |  볼륨(24시간):